HTML Microdata document

This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/pdb/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n26	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/kegg-compound/
n21	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/pubchem-compound/
n8	http://linked.opendata.cz/resource/AHFS/
n15	http://linked.opendata.cz/resource/drugbank/company/
n17	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/pubchem-substance/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/kegg-drug/
n28	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/drugbank/
n10	http://bio2rdf.org/drugbank:
n13	http://www.drugs.com/cons/
adms	http://www.w3.org/ns/adms#
n18	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n27	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/chemspider/
n14	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n16	http://linked.opendata.cz/ontology/mesh/
n5	http://linked.opendata.cz/ontology/drugbank/
n25	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/chebi/
n6	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/pharmgkb/
n4	http://linked.opendata.cz/resource/drugbank/drug/DB00592/identifier/wikipedia/
n19	http://linked.opendata.cz/resource/atc/
n7	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00592
rdf:type: n5:Drug
n5:description: Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Piperazine exists as small alkaline deliquescent crystals with a saline taste. Piperazine was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Piperazine was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic action. Their mode of action is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.
n5:group: approved
n5:indication: Used as alternative treatment for ascariasis caused by Ascaris lumbricoides (roundworm) and enterobiasis (oxyuriasis) caused by Enterobius vermicularis (pinworm). It is also used to treat partial intestinal obstruction by the common roundworm, a condition primarily occurring in children.
n5:manufacturer: n15:271B51E5-363D-11E5-9242-09173F13E4C5 n15:271B51E6-363D-11E5-9242-09173F13E4C5 n15:271B51DF-363D-11E5-9242-09173F13E4C5 n15:271B51E0-363D-11E5-9242-09173F13E4C5 n15:271B51DE-363D-11E5-9242-09173F13E4C5 n15:271B51E3-363D-11E5-9242-09173F13E4C5 n15:271B51E4-363D-11E5-9242-09173F13E4C5 n15:271B51E1-363D-11E5-9242-09173F13E4C5 n15:271B51E2-363D-11E5-9242-09173F13E4C5
owl:sameAs: n10:DB00592 n18:DB00592
dcterms:title: Piperazine
adms:identifier: n4:Piperazine n20:PA450977 n21:4837 n22:D00807 n23:169 n24:46507642 n25:28568 n26:C07973 n27:13835459 n28:DB00592
n5:mechanismOfAction: Piperazine is a GABA receptor agonist. Piperzine binds directly and selectively to muscle membrane GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm. While the worm is paralyzed, it is dislodged from the intestinal lumen and expelled live from the body by normal intestinal peristalsis.
n5:packager: n15:271B51DD-363D-11E5-9242-09173F13E4C5
n5:synonym: Diethylenediamine Vermizine (tn) Piperazidine Piperazin Piperazine
n5:toxicity: LD50 = 5 g/kg (Human, oral). Symptoms of overdose include muscle fatigue, seizures, and difficulty breathing.
n7:hasAHFSCode: n8:92-02-00%2A n8:08-08-00
n5:foodInteraction: Take without regard to meals.
n5:proteinBinding: 60-70%
n5:salt
n5:synthesisReference: Hong-Xin Li, Jose Guadalupe Santiesteban, Lenore Ann Emig, John Nelson Armor, "Triethylenediamine and piperazine synthesis using zeolite catalysts modified with a silicon-containing compound." U.S. Patent US6084096, issued 0000.
n16:hasConcept: n17:M0107342
foaf:page: n13:piperazine.html
n5:IUPAC-Name: n6:271B51F2-363D-11E5-9242-09173F13E4C5
n5:InChI: n6:271B51F8-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n6:271B51F7-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n6:271B51F4-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n6:271B51F5-363D-11E5-9242-09173F13E4C5
n5:SMILES: n6:271B51F6-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility: n6:271B5207-363D-11E5-9242-09173F13E4C5 n6:271B51F0-363D-11E5-9242-09173F13E4C5
n5:logP: n6:271B520A-363D-11E5-9242-09173F13E4C5 n6:271B51F1-363D-11E5-9242-09173F13E4C5 n6:271B51EE-363D-11E5-9242-09173F13E4C5
n5:logS: n6:271B520B-363D-11E5-9242-09173F13E4C5 n6:271B51EF-363D-11E5-9242-09173F13E4C5
n5:pKa: n6:271B520C-363D-11E5-9242-09173F13E4C5
n7:hasATCCode: n19:P02CB01
n5:H-Bond-Acceptor-Count: n6:271B51FE-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n6:271B51FF-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n6:271B51F9-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n6:271B51FA-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n6:271B51FC-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n6:271B51FB-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n6:271B51FD-363D-11E5-9242-09173F13E4C5
n5:absorption: Rapidly absorbed from the gastrointestinal tract
n5:affectedOrganism: Parasitic nematodes and other roundworms
n5:casRegistryNumber: 110-85-0
n5:category
n5:containedIn: n14:271B51EB-363D-11E5-9242-09173F13E4C5 n14:271B51EC-363D-11E5-9242-09173F13E4C5 n14:271B51E9-363D-11E5-9242-09173F13E4C5 n14:271B51EA-363D-11E5-9242-09173F13E4C5 n14:271B51E7-363D-11E5-9242-09173F13E4C5 n14:271B51E8-363D-11E5-9242-09173F13E4C5 n14:271B51ED-363D-11E5-9242-09173F13E4C5
n5:Bioavailability: n6:271B5203-363D-11E5-9242-09173F13E4C5
n5:Boiling-Point: n6:271B5209-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n6:271B5205-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n6:271B5206-363D-11E5-9242-09173F13E4C5
n5:Melting-Point: n6:271B5208-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n6:271B5202-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n6:271B5201-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n6:271B5204-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n6:271B51F3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n6:271B5200-363D-11E5-9242-09173F13E4C5